News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
727,861 Results
Type
Article (43120)
Company Profile (458)
Press Release (684266)
Multimedia
Podcasts (105)
Webinars (19)
Section
Business (209085)
Career Advice (2029)
Deals (36074)
Drug Delivery (108)
Drug Development (83796)
Employer Resources (174)
FDA (16581)
Job Trends (15158)
News (353600)
Policy (33234)
Tag
Academia (2647)
Accelerated approval (18)
Adcomms (28)
Allergies (116)
Alliances (51108)
ALS (138)
Alzheimer's disease (1605)
Antibody-drug conjugate (ADC) (206)
Approvals (16633)
Artificial intelligence (401)
Autoimmune disease (64)
Automation (25)
Bankruptcy (373)
Best Places to Work (11840)
BIOSECURE Act (20)
Biosimilars (145)
Biotechnology (331)
Bladder cancer (122)
Brain cancer (47)
Breast cancer (460)
Cancer (3647)
Cardiovascular disease (304)
Career advice (1705)
Career pathing (33)
CAR-T (226)
CDC (44)
Cell therapy (615)
Cervical cancer (30)
Clinical research (69635)
Collaboration (1312)
Company closure (4)
Compensation (917)
Complete response letters (50)
COVID-19 (2729)
CRISPR (78)
C-suite (551)
Cystic fibrosis (130)
Data (4207)
Decentralized trials (2)
Denatured (34)
Depression (101)
Diabetes (411)
Diagnostics (6583)
Digital health (33)
Diversity (10)
Diversity, equity & inclusion (45)
Drug discovery (187)
Drug pricing (162)
Drug shortages (29)
Duchenne muscular dystrophy (199)
Earnings (89901)
Editorial (49)
Employer branding (21)
Employer resources (151)
Events (118648)
Executive appointments (941)
FDA (18910)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (5)
Frontotemporal dementia (14)
Funding (1184)
Gene editing (167)
Generative AI (29)
Gene therapy (505)
GLP-1 (894)
Government (4689)
Grass and pollen (5)
Guidances (334)
Healthcare (19187)
HIV (44)
Huntington's disease (36)
IgA nephropathy (54)
Immunology and inflammation (214)
Immuno-oncology (16)
Indications (52)
Infectious disease (2940)
Inflammatory bowel disease (175)
Inflation Reduction Act (15)
Influenza (86)
Intellectual property (180)
Interviews (314)
IPO (16895)
IRA (51)
Job creations (3710)
Job search strategy (1437)
Kidney cancer (13)
Labor market (67)
Layoffs (563)
Leadership (25)
Legal (8014)
Liver cancer (86)
Longevity (11)
Lung cancer (523)
Lymphoma (255)
Machine learning (28)
Management (59)
Manufacturing (578)
MASH (130)
Medical device (13736)
Medtech (13756)
Mergers & acquisitions (20033)
Metabolic disorders (1044)
Multiple sclerosis (132)
NASH (19)
Neurodegenerative disease (209)
Neuropsychiatric disorders (54)
Neuroscience (2577)
NextGen: Class of 2025 (6758)
Non-profit (4562)
Now hiring (56)
Obesity (503)
Opinion (256)
Ovarian cancer (122)
Pain (148)
Pancreatic cancer (162)
Parkinson's disease (231)
Partnered (27)
Patents (392)
Patient recruitment (291)
Peanut (53)
People (59571)
Pharmaceutical (85)
Pharmacy benefit managers (24)
Phase I (21865)
Phase II (30732)
Phase III (22677)
Pipeline (2610)
Policy (255)
Postmarket research (2602)
Preclinical (9391)
Press Release (67)
Prostate cancer (186)
Psychedelics (49)
Radiopharmaceuticals (275)
Rare diseases (614)
Real estate (6044)
Recruiting (69)
Regulatory (23842)
Reports (51)
Research institute (2443)
Resumes & cover letters (352)
Rett syndrome (14)
RNA editing (15)
RSV (61)
Schizophrenia (128)
Series A (199)
Series B (149)
Service/supplier (11)
Sickle cell disease (78)
Special edition (24)
Spinal muscular atrophy (154)
Sponsored (35)
Startups (3788)
State (2)
Stomach cancer (15)
Supply chain (92)
Tariffs (80)
The Weekly (69)
Vaccines (911)
Venture capital (64)
Weight loss (331)
Women's health (55)
Worklife (18)
Date
Today (91)
Last 7 days (524)
Last 30 days (2262)
Last 365 days (31426)
2025 (24145)
2024 (36300)
2023 (41015)
2022 (52277)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33023)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (743)
Alabama (77)
Alaska (7)
Arizona (273)
Arkansas (14)
Asia (40018)
Australia (6651)
California (9098)
Canada (2778)
China (835)
Colorado (384)
Connecticut (401)
Delaware (246)
Europe (87725)
Florida (1336)
Georgia (296)
Hawaii (2)
Idaho (60)
Illinois (720)
India (43)
Indiana (430)
Iowa (19)
Japan (303)
Kansas (119)
Kentucky (35)
Louisiana (17)
Maine (67)
Maryland (1200)
Massachusetts (6762)
Michigan (277)
Minnesota (530)
Mississippi (4)
Missouri (107)
Montana (31)
Nebraska (25)
Nevada (101)
New Hampshire (73)
New Jersey (2493)
New Mexico (30)
New York (2466)
North Carolina (1302)
North Dakota (9)
Northern California (4147)
Ohio (276)
Oklahoma (19)
Oregon (40)
Pennsylvania (1906)
Puerto Rico (18)
Rhode Island (44)
South America (1113)
South Carolina (45)
South Dakota (1)
Southern California (3494)
Tennessee (145)
Texas (1401)
United States (33195)
Utah (265)
Virginia (223)
Washington D.C. (77)
Washington State (773)
West Virginia (4)
Wisconsin (80)
Wyoming (1)
727,861 Results for "assertio therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Assertio Holdings, Inc. to Report Second Quarter 2025 Financial Results on August 11, 2025
August 6, 2025
·
1 min read
Press Releases
Assertio to Participate in the HC Wainwright and Lake Street Conferences in September 2025
September 4, 2025
·
1 min read
Press Releases
Assertio Reports Second Quarter 2025 Financial Results
August 12, 2025
·
24 min read
Press Releases
Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN® (clobazam) Oral Film, CIV
September 16, 2025
·
14 min read
Press Releases
Assertio Holdings, Inc. to Report First Quarter 2025 Financial Results on May 12, 2025
May 6, 2025
·
1 min read
Press Releases
Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN® at upcoming 150th Annual Meeting of the American Neurological Association
September 10, 2025
·
13 min read
Press Releases
Assertio Reports First Quarter 2025 Financial Results
May 13, 2025
·
20 min read
Press Releases
Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors
December 18, 2024
·
4 min read
Business
Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024
Assertio Holdings, Inc., a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that it will release first quarter 2024 financial results on Monday, May 6, 2024, after the market close.
April 25, 2024
·
1 min read
BioMidwest
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - June 06, 2024
Assertio Holdings, Inc. announced that effective May 31, 2024, the Compensation Committee of the Company’s Board of Directors granted the Company’s new Chief Executive Officer, Brendan P. O’Grady, 500,000 restricted stock units and 1,800,000 stock options.
June 6, 2024
·
3 min read
1 of 72,787
Next
